Jupiter Wellness To Offer Clinical Research Services With Acquisition Of Ascent Clinical Research

Jupiter Wellness, Inc. JUPW has concluded an asset purchase agreement with Ascent Clinical Research, Inc. through which it has acquired certain clinical assets including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets.

"This strategic asset purchase agreement adds immediate revenues to Jupiter in Q2 2022 and contributes positively towards EBITDA with no upfront cash or stock acquisition cost to our company. The acquired contracts and related assets enhance Jupiter's position as a research and development powerhouse while allowing us to enter the lucrative clinical research organization business," stated Jupiter CEO Brian John.

Photo: Courtesy of Jupiter Wellness, Inc.

Related News

Jupiter Wellness To Dividend SRM Entertainment Subsidiary To Its Stockholders

The Link Between Cannabis Consumption and Sleep — Cannabis Daily December 10, 2021

Jupiter Wellness & Next Frontier Pharmaceuticals Merge, Will Expand Cannabinoid & Psychedelics Drug Development


Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us September 13-14, 2022 at The Palmer House in Chicago, IL.

Posted In: Ascent Clinical Research IncBrian JohnCannabisNewsPenny StocksMarkets